Newsletter registration

By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Bridge to New Markets.

MSD invests USD 220 million in Krems

logo MSD © MSD

MSD intends to invest about USD 220 million over the next four to five years in the expansion of the existing Baxter facility, and will create approx. 400 new jobs.

The new production plant will primarily manufacture vaccines. “On the basis of this acquisition, we are positioning ourselves for strong, long-term growth”, states Joseph Morrissey, Vice President of MSD Animal Health. After completing adaptations to the site, the company plans to commence vaccine production in two years. MSD already operates a manufacturing facility in Vienna for veterinary pharmaceuticals via its subsidiary Intervet. It mainly produces hormones, tick protection and control products, cardiovascular medicines and antibiotics. The animal medicines are exported for the most part, especially to the USA. Merck’s animal health division is represented in 50 countries, and its products are available in 150 markets worldwide.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • 17. Mittelstandstag FrankfurtRheinMain

    07.11.2019, Frankfurt on the Main, Germany

  • MEDICA 2019

    18.11.- 21.11. 2019, Dusseldorf, Germany, Germany

Austria Map

Find the perfect location for your company

Austria offers the comfort and infrastracture of a western industrial nation. The high quality of life is an advantage when it comes to attracting top executives from around the world to our headquarters here.

Coca-Cola Austria

Logo
More testimonials

news from the business location Austria

Siemens: New robot welding plant in Graz

Siemens Mobility has put a new robot-controlled frame welding facility into operation in Graz.

Coming back for seconds: Why big brands expand their (R&D) presence in Austria

The high-tech multinational Infineon is investing more than EUR 1.6 billion to expand its main facility in Austria. The pharmaceutical company Octapharma is massively expanding its Vienna-based operations at a cost of EUR 142 million. Headlines like these have recently caused people to sit up and take notice. But the question is: why is Austria as a research location so popular with international firms which are already established here?

More news All blog posts